Median Technologies forms strategic review committee, names Oern Stuge chair
Reuters2026/09/02 15:45- Median Technologies created a Strategic Review Committee to assess structural and financial options to lift shareholder value.
- Scope includes a potential separation of iCRO from eyonis, potential U.S. listing, other strategic alternatives.
- Oern Stuge will chair the committee; the former Medtronic executive has led EMEA and emerging markets, cardiac surgery businesses.
- A new board-level R&D Committee will oversee scientific priorities and the expansion of the eyonis platform beyond lung cancer screening.
- Kapil Dhingra will chair the R&D Committee; he previously led oncology clinical development at Roche, worked at MD Anderson.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Santander Bank: Japan GPIF does not need to adjust asset allocation policy, $62 billion may face sell-off
Analysts at Spain's Santander Bank stated that Japan’s Government Pension Investment Fund (GPIF) could potentially sell up to $62 billion worth of U.S. Treasury bonds without needing to formally adjust its asset allocation policy.
Health in Tech director Timothy Hayes sells 17,730 common shares for $16,243.80
Ocugen CEO Shankar Musunuri sells common shares worth $589,430.24
Computer Modelling Group held annual shareholder meeting
Crypto prices
More
